Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Clostridium botulinum (tested or 100% immunogen sequence identity)
Tissue culture supernatant
Specificity and Use
Botulinum Neurotoxin Type A antibody was raised against synthetic peptide analog of the carboxyl terminal region of BoTox-A.
Recognizes BoTox-A (1280-1292), and BoTox-A, but does not react with BoTox-B, BoTox-C, BoTox-E, or BoTox-F (1272-1280). Binds to intact whole BoTox-A by ELISA, RIA and cell staining techniques. Found to inhibit the binding of BoTox-A to Neuro2A cells treated with GT1b ganglioside prior to the addition of the toxin, and prior incubation of the antibody with the synthetic peptide immunogen has been shown to eliminate the inhibition of cellular binding by the antibody.
Suitable for use in ELISA, RIA, Immunofluorescence and Inhibition of BoTox-A binding to Neuro2A Cells. The staining pattern was observed using epifluorescent microscopy. Inhibition: Inhibits the binding of BoTox-A to Neuro2A cells treated with GT1b ganglioside prior to the addition of the toxin, and prior incubation of the antibody with the synthetic peptide. The immunogen has been shown to eliminate the inhibition of cellular binding by the antibody.
Supplied as a liquid.
Long term: -20°C; Short term: +4°C. Avoid repeat freeze-thaw cycles.